💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Pegunigalsidase Alfa

CHEMBL4297801 Phase 4 Onaylandı Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
560.6 g/mol
LogP
-8.0
Phase
4

A PEGylated plant-cell-expressed recombinant alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a lysosomal storage disorder. Longer half-life from PEGylation allows biweekly dosing, and it reduces the accumulation of globotriaosylceramide in tissues.

Moleküler Ağırlık

560,6000 g/mol

LogP

-8,00

TPSA

252,00 Ų

Lipinski RO5

Başarısız

Etki Mekanizması

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

SMILES

C(CCNC(=O)CCC(=O)NCCOCCNC(=O)CCC(=O)NCCCC[C@@H](C(=O)O)N)C[C@@H](C(=O)O)N

InChI

InChI=1S/C24H44N6O9/c25-17(23(35)36)5-1-3-11-27-19(31)7-9-21(33)29-13-15-39-16-14-30-22(34)10-8-20(32)28-12-4-2-6-18(26)24(37)38/h17-18H,1-16,25-26H2,(H,27,31)(H,28,32)(H,29,33)(H,30,34)(H,35,36)(H,37,38)/t17-,18-/m0/s1

Molecular Formula

C24H44N6O9

HBD / HBA

8 / 11

Döndürülebilir Bağlar

24

Ağır Atomlar

39

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A PEGylated plant-cell-expressed recombinant alpha-galactosidase A enzyme replacement therapy used to treat Fabry disease, a lysosomal storage disorder. Longer half-life from PEGylation allows biweekly dosing, and it reduces the accumulation of globotriaosylceramide in tissues.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Pegunigalsidase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297801. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 121488171. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.